

Grifols streamlines its global plasma network with the closure of 29 donation centers in the U.S.

- *Increasing productivity and collections by center and improved network utilization while continuing to grow US plasma collection volumes to support long-term growth in the US*
- *The initiative includes the consolidation of operations into higher-performing locations, while providing alternative options for donors to ensure continuity*
- *EMA approval of Egyptian plasma, together with largest center network in Europe, provides scalable source for ex-US growth*
- *Allows to reduce use of US plasma for ex-US markets in the future and thus focus growing US collections on US market with its strong growth outlook*
- *Supports Grifols' strategic priority of margin-led EBITDA growth*

Barcelona, Spain, April 24, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced a targeted optimization of its plasma donation center network in the United States, where the company is the leading plasma operator with more than 300 centers. This initiative is part of a broader, ongoing strategy to enhance the productivity, efficiency and long-term sustainability of its U.S. plasma platform.

The initiative includes the closure of 29 centers, alongside the consolidation of operations into higher-performing locations. This process is designed to enhance productivity per center, improve plasma collection efficiency and overall yield across the network and reinforce the resilience of plasma supply, in line with Grifols' strategic focus on delivering margin-led EBITDA growth.

The optimization will be implemented over the coming weeks, with affected centers operating during a short transition to ensure a smooth transition for donors while reinforcing the performance of the overall network. Donors from affected centers will be redirected to nearby Grifols locations, ensuring continuity and maintaining a safe, high-quality donation experience.

Despite this footprint optimization, Grifols expects to grow its overall plasma collection volumes in the US, supported by higher productivity per center and improved utilization of its network.

Jordi Balsells, President Plasma Procurement, said: "We have a clear opportunity to drive efficiencies with our US plasma collections and thereby contribute to our margin improvement objective whilst continuing to grow US plasma collection volumes to support the continued strong growth prospects of plasma derived medicines in the US."

The recent game-changing EMA approval of highly scalable source plasma from Egypt, together with the largest plasma collection network in Europe, offers a clear opportunity to reduce the use of US plasma for ex-us markets in the future and focus growing US collections on the US market with its

strong growth outlook. Further, increasing productivity and collections by center, as well as improved network utilization, allows for streamlining of Grifols' donor center network in the US whilst continuing to grow the US plasma collection volumes to support the strong growth needs for plasma derived medicines in the US market.

Performance-driven optimization and scalable U.S. platform

This decision follows a rigorous and continuous performance review of the whole U.S network. Over the past year, Grifols has implemented multiple operational initiatives aimed at enhancing performance across its plasma centers. Building on this process, the company is now prioritizing centers with stronger performance and greater growth potential, reallocating resources to those locations where it can deliver higher productivity, improved efficiency and more consistent results over time.

Plasma collection in the U.S. is the foundation of Grifols' vertically integrated model, supported by significant industrial operations in California and North Carolina, a workforce of more than 14,000 employees nationwide. This combination of scale, full vertical integration and a nationwide footprint underpins a highly resilient platform capable of sustaining long-term growth and value creation, supported by ongoing improvements in donor experience and retention across the network.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Phone: +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability

investors@grifols.com – inversores@grifols.com

sustainability@grifols.com – sostenibilidad@grifols.com

Phone: +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.